QT/QTc safety and efficacy evaluation of teneligliptin in Indian type 2 diabetes mellitus patients: the “thorough QT/QTc” study (Q-SET study)
S Erande,1 S Sarwardekar,2 B Desai31Department of Medicine, Akshay Hospital, Pune 411004, India; 2Department of Medicine, Sawardekar Clinic, Mumbai 400055, India; 3Department of Cardiology, Desai Heart Care Clinic, Mumbai 400092, IndiaBackground: Newer therapies, such as dipeptidyl peptidase-IV inhi...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2019
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/bcd0d7c60b31454482b6784b0fcd1f5d |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:bcd0d7c60b31454482b6784b0fcd1f5d |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:bcd0d7c60b31454482b6784b0fcd1f5d2021-12-02T12:17:14ZQT/QTc safety and efficacy evaluation of teneligliptin in Indian type 2 diabetes mellitus patients: the “thorough QT/QTc” study (Q-SET study)1178-7007https://doaj.org/article/bcd0d7c60b31454482b6784b0fcd1f5d2019-06-01T00:00:00Zhttps://www.dovepress.com/qtqtc-safety-and-efficacy-evaluation-of-teneligliptin-in-indian-type-2-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007S Erande,1 S Sarwardekar,2 B Desai31Department of Medicine, Akshay Hospital, Pune 411004, India; 2Department of Medicine, Sawardekar Clinic, Mumbai 400055, India; 3Department of Cardiology, Desai Heart Care Clinic, Mumbai 400092, IndiaBackground: Newer therapies, such as dipeptidyl peptidase-IV inhibitors, are increasingly being used in the treatment of type 2 diabetes mellitus (T2DM). Teneligliptin, a DPP4 inhibitor, currently commonly used as monotherapy or as add-on therapy, was generally well tolerated in patients with T2DM during clinical trials. No AEs related to QT prolongation were detected with 40 mg/day of teneligliptin, but were seen at a supratherapeutic dose of 160 mg/day.Aims and objective: To evaluate the safety of teneligliptin in type 2 diabetes patients with respect to QTc prolongation.Methodology: This was an open-label, prospective, multi-centric trial conducted in patients with T2DM aged ≥18 to ≤65 years with a hemoglobin A1c (HbA1c) ≥7.0% and gliptin naïve. Teneligliptin 20 mg once a day was added to the standard treatment. The dose of teneligliptin was increased to 40 mg once a day if required, on the basis of glycemic parameters. Twelve-lead ECG was recorded at baseline and follow-up visits. The QTc was calculated by using the Bazett’s formula (QTc=QT/√RR).Results: The mean QT interval at screening (Visit 1, Day 0, baseline ECG) was 0.33±0.07 seconds, while at visit 2 (Day 1, post 2 hours of Teneligliptin dosing) it was 0.32±0.04 seconds, at visit 3 (Day 15) it was 0.32±0.04 seconds, and at visit 4 (Day 90) it was 0.32±0.03 seconds. The mean QTc interval at baseline was 0.37±0.04 seconds, while at visit 2 it was 0.37±0.04 seconds, at visit 3 it was 0.37±0.03 seconds, and at visit 4 it was 0.37±0.03 seconds. There was a significant reduction in fasting blood glucose (P=0.002), postprandial blood glucose (P<0.001), and HbA1c (P<0.001) at the end of the 3 months as compared to baseline.Conclusion: Teneligliptin at a therapeutic dose of 20 mg/day or 40 mg/day improved glycemic parameters significantly and did not cause QT/QTc interval prolongation.Keywords: diabetes, teneligliptin, QT prolongationErande SSarwardekar SDesai BDove Medical PressarticleDiabetesTeneligliptinQT ProlongationSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 12, Pp 961-967 (2019) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Diabetes Teneligliptin QT Prolongation Specialties of internal medicine RC581-951 |
| spellingShingle |
Diabetes Teneligliptin QT Prolongation Specialties of internal medicine RC581-951 Erande S Sarwardekar S Desai B QT/QTc safety and efficacy evaluation of teneligliptin in Indian type 2 diabetes mellitus patients: the “thorough QT/QTc” study (Q-SET study) |
| description |
S Erande,1 S Sarwardekar,2 B Desai31Department of Medicine, Akshay Hospital, Pune 411004, India; 2Department of Medicine, Sawardekar Clinic, Mumbai 400055, India; 3Department of Cardiology, Desai Heart Care Clinic, Mumbai 400092, IndiaBackground: Newer therapies, such as dipeptidyl peptidase-IV inhibitors, are increasingly being used in the treatment of type 2 diabetes mellitus (T2DM). Teneligliptin, a DPP4 inhibitor, currently commonly used as monotherapy or as add-on therapy, was generally well tolerated in patients with T2DM during clinical trials. No AEs related to QT prolongation were detected with 40 mg/day of teneligliptin, but were seen at a supratherapeutic dose of 160 mg/day.Aims and objective: To evaluate the safety of teneligliptin in type 2 diabetes patients with respect to QTc prolongation.Methodology: This was an open-label, prospective, multi-centric trial conducted in patients with T2DM aged ≥18 to ≤65 years with a hemoglobin A1c (HbA1c) ≥7.0% and gliptin naïve. Teneligliptin 20 mg once a day was added to the standard treatment. The dose of teneligliptin was increased to 40 mg once a day if required, on the basis of glycemic parameters. Twelve-lead ECG was recorded at baseline and follow-up visits. The QTc was calculated by using the Bazett’s formula (QTc=QT/√RR).Results: The mean QT interval at screening (Visit 1, Day 0, baseline ECG) was 0.33±0.07 seconds, while at visit 2 (Day 1, post 2 hours of Teneligliptin dosing) it was 0.32±0.04 seconds, at visit 3 (Day 15) it was 0.32±0.04 seconds, and at visit 4 (Day 90) it was 0.32±0.03 seconds. The mean QTc interval at baseline was 0.37±0.04 seconds, while at visit 2 it was 0.37±0.04 seconds, at visit 3 it was 0.37±0.03 seconds, and at visit 4 it was 0.37±0.03 seconds. There was a significant reduction in fasting blood glucose (P=0.002), postprandial blood glucose (P<0.001), and HbA1c (P<0.001) at the end of the 3 months as compared to baseline.Conclusion: Teneligliptin at a therapeutic dose of 20 mg/day or 40 mg/day improved glycemic parameters significantly and did not cause QT/QTc interval prolongation.Keywords: diabetes, teneligliptin, QT prolongation |
| format |
article |
| author |
Erande S Sarwardekar S Desai B |
| author_facet |
Erande S Sarwardekar S Desai B |
| author_sort |
Erande S |
| title |
QT/QTc safety and efficacy evaluation of teneligliptin in Indian type 2 diabetes mellitus patients: the “thorough QT/QTc” study (Q-SET study) |
| title_short |
QT/QTc safety and efficacy evaluation of teneligliptin in Indian type 2 diabetes mellitus patients: the “thorough QT/QTc” study (Q-SET study) |
| title_full |
QT/QTc safety and efficacy evaluation of teneligliptin in Indian type 2 diabetes mellitus patients: the “thorough QT/QTc” study (Q-SET study) |
| title_fullStr |
QT/QTc safety and efficacy evaluation of teneligliptin in Indian type 2 diabetes mellitus patients: the “thorough QT/QTc” study (Q-SET study) |
| title_full_unstemmed |
QT/QTc safety and efficacy evaluation of teneligliptin in Indian type 2 diabetes mellitus patients: the “thorough QT/QTc” study (Q-SET study) |
| title_sort |
qt/qtc safety and efficacy evaluation of teneligliptin in indian type 2 diabetes mellitus patients: the “thorough qt/qtc” study (q-set study) |
| publisher |
Dove Medical Press |
| publishDate |
2019 |
| url |
https://doaj.org/article/bcd0d7c60b31454482b6784b0fcd1f5d |
| work_keys_str_mv |
AT erandes qtqtcsafetyandefficacyevaluationofteneligliptininindiantype2diabetesmellituspatientstheldquothoroughqtqtcrdquostudyqsetstudy AT sarwardekars qtqtcsafetyandefficacyevaluationofteneligliptininindiantype2diabetesmellituspatientstheldquothoroughqtqtcrdquostudyqsetstudy AT desaib qtqtcsafetyandefficacyevaluationofteneligliptininindiantype2diabetesmellituspatientstheldquothoroughqtqtcrdquostudyqsetstudy |
| _version_ |
1718394534997524480 |